# PairX Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pairx-bio

- Industry: Biotechnology
- Headquarters: Singapore, Singapore
- Website: www.pairxbio.com
- Total disclosed funding: $9.8M
- Latest round: Seed (Apr 14, 2022)
- Investors on record: 2

## About

Founded in 2020 and based in Singapore, PairX Bio Pte Ltd, dba PairX Bio focuses on the development of next-generation cancer immunotherapies that target common tumor-associated antigens produced from spliced proteins. The company was incubated by EVX Ventures and spun out from Duke-NUS. 

The company is developing next-generation cancer immunotherapies that target shared tumor-associated antigens produced from spliced proteins that are abnormally spliced. The firm's platform is based on mRNA splicing biology, which, when paired with its patented antigen and T Cell validation procedures, allows it to validate tumor antigen-T Cell pairs in numerous patient-derived tumors at the same time.

?

## Funding rounds

- Seed, Apr 14, 2022, $9.8M — Versant Ventures, NUS Technology

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Seed
- NUS Technology — Seed